IMO-T 2.13 CGI-T -0.07 AC-T -0.05 LNR-T 1.37 LLY-N 105.06 META-Q -0.83 NVDA-Q -3
Daily Stock Opinions and Ratings
Stockchase Opinions

Richard Bernstien Biomet Inc BMET-Q TOP PICK Sep 17, 2004

Health care looks very attractive.
Richard BernstienRichard Bernstien
No
Unlock Rating
$47.470

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.
Get Signals Create your Watchlist

You might be interested:

TOP PICK

Biomet Inc(BMET-Q)

Oct 16, 2001
Medical devices have been holding up well and Biomet is the world leader in orthopedic devices. Growing revenues. Some competition.
David BurrowsDavid Burrows
Unknown
Unlock Rating
$32.130

Stock price when the opinion was issued

biotechnology pharmaceutical
PAST TOP PICK

Biomet Inc(BMET-Q)

Apr 22, 2003
(Was a top pick on Feb 13. Up 8%.) Still likes. Would continue to buy under $30.
Brad WillockBrad Willock
Unknown
Unlock Rating
$30.610

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Biomet Inc(BMET-Q)

May 23, 2003
A little volatile. No debt. Earnings growth is 15/20% a year. Has a lot of sales in Europe which acts as a hedge on currency. Age demographics means more demand for their products.
Brad WillockBrad Willock
Unknown
Unlock Rating
$28.430

Stock price when the opinion was issued

biotechnology pharmaceutical
PAST TOP PICK

Biomet Inc(BMET-Q)

Jul 17, 2003
(Was a top pick on May 23/03. No change.) An age demographic play.
Brad WillockBrad Willock
Unknown
Unlock Rating
$28.490

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Biomet Inc(BMET-Q)

Nov 12, 2004
Generally cautious on the mainstream pharmaceutical companies, but this company is well positioned to benefit from the aging baby boomers with artificial hips and knees.
Christine CalliesChristine Callies
No
Unlock Rating
$48.530

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Biomet Inc(BMET-Q)

Mar 29, 2005
Primary business is the hip/knee replacements. What has generated a product cycle recently is that they can do hips less invasively with only small incisions and knees can be replaced. Stock has been coming off recently. Trades around 19 X earnings. Top line growth is 15% and earnings closer to 20%.
Danny TomkaDanny Tomka
Owned
Unlock Rating
$38.760

Stock price when the opinion was issued

biotechnology pharmaceutical
TOP PICK

Biomet Inc(BMET-Q)

Jun 02, 2005
Has $2 billion in sales. Knee and hip business. Likes this business. Great demographics with an older population. Wonderful cash flow earnings growth. Limited competition so reasonably stable.
Danny TomkaDanny Tomka
Owned
Unlock Rating
$38.220

Stock price when the opinion was issued

biotechnology pharmaceutical

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Latest Buy Signals

HRTG-N 1.07$18.87
EIF-T 0.37$48.84
MRK-N 1.54$78
MDI-T -0.11$8.3
DBM-T 0.03$6.86
Advertising

Today's Top Picks

IMO-T 2.13$88.37
CGI-T -0.07$33
AC-T -0.05$13.97
LNR-T 1.37$48.15
LLY-N 105.06$839.96

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

RH-N 7.28$161.13
LVMUY-… 0$108.93
NXPI-Q 2.15$170.74
DAL-N 0.26$40.85
AMD-Q -0.79$87.5

Most Recent Experts

Bruce Murray

The Murray Wealth Group

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Chris Blumas

at Raymond James Investment Counsel Ltd.

Stockchase Insights

5i Research

Advertising
Advertising
© Stockchase Inc.